Next-gen biotechs pursue 'undruggable' targets

A crop of up-and-coming developers, including Anchor Therapeutics, Aileron Therapeutics, Forma Therapeutics and NeurAxon--are among the new wave of biotechs that seek to successfully hit molecular targets that Big Pharma has missed for decades. "[Going after undruggable targets] is a risk we take," Rick Jones, CEO of Anchor Therapeutics, tells TheScientist. "People have been banging on it for so long that they have gotten tired of it or just assume it can't be done." Read more

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.